Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.
about
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisMultiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencingA pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylationPhospholipid and sphingolipid metabolism in Leishmania.Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in miceIn vitro and in vivo interactions between miltefosine and other antileishmanial drugsStructures, targets and recent approaches in anti-leishmanial drug discovery and development.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine: oral treatment of leishmaniasis.Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Possible mechanism of miltefosine-mediated death of Leishmania donovani.Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.Drug delivery systems in the treatment of African trypanosomiasis infections.Determination of antiprotozoal drug mechanisms by metabolomics approaches.Lipids and cell death in yeast.Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania.Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulatorLeishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance.Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.Edelfosine induces an apoptotic process in Leishmania infantum that is regulated by the ectopic expression of Bcl-XL and Hrk.Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.Phospholipases a in trypanosomatids.Characterization of the inositol phosphorylceramide synthase activity from Trypanosoma cruzi.The use of natural and synthetic phospholipids as pharmaceutical excipients.Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions.Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.A complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine.Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites.
P2860
Q24538756-5500B676-9B87-4EFF-B92F-1F16F2404E0EQ24538777-AADC29BC-E1E5-4B81-9561-706D0537BFC4Q27930460-D26B8C32-4E74-4B56-A752-BE08EC0D450FQ28271849-AC936EC4-D7F0-453E-B81E-15295039D70AQ28480626-FF191018-F4AF-48C5-B858-5241D57458D9Q30046703-475712F6-7B79-42DE-B3E1-1E2254260FD4Q33625755-BAC9CDE2-C6DA-49B0-B110-F2B4F48409E8Q34044853-D5CA3FE1-20CC-4AD8-B077-3BEFD96FA093Q34301638-2F5AAE68-3630-4579-8AC2-FB796CE9843EQ35012968-66FBC314-93EB-44DE-8A01-CBBFB3ECD393Q35606296-69BE5580-63ED-4794-BD1D-469EC76EA934Q36441483-82DA960E-6364-4795-8095-E4ABFE29404BQ36576096-FB2F1F56-A8FA-4ED8-B625-B86CDDDC8139Q36669276-CF5C8C80-3A4F-4C5D-AFCF-B3FEDC754C4AQ37450724-894D66D4-31B5-49D5-921C-D92F968EFB82Q37876880-912E0C5E-C096-418E-AA7D-F5738702F125Q38111816-DAE93220-3C23-4C03-B221-2FAB9F3BBCDBQ38151973-24EF3EA4-D4EA-4A2C-979F-B9E838D66CF2Q38458645-19C1C974-1D7B-4E36-A39C-268C48D2CA20Q38626366-9F9FF349-80DF-4C2F-BB06-AE990B629DF9Q39478185-378A3623-8155-4AF0-A7EF-A03AC5578732Q39792515-A88B89A5-E208-4B3E-AA54-19EAEE2C9ADCQ40084369-DAD9238C-F7FB-469B-A068-828648AD3167Q40099567-620D6FC5-2840-4797-8CE7-00C2973C5C44Q40174125-1169BFD5-E2FD-4BCE-A2B3-C8C15D6D3483Q40622211-575ED1AA-C69C-4D08-BCAA-DA7936588E91Q41038675-7C7690F7-A3BA-4506-9668-8A100427B141Q41893418-A9C486D1-D8CB-4D9F-BD2B-FDF80BFD8279Q41981234-DF677A0B-F41C-431A-84CA-DF0BF5CB28BDQ42067834-EE9F79FA-C635-4F0B-AB5A-FDC189E57D39Q42588360-44AC4144-6785-410B-A2C9-8F56BAC7FF48Q42716413-D3378406-42F1-40D1-9A36-0085B41B8C6DQ42816185-8A924045-8287-49EC-8764-CEBF1DC7947CQ42957861-A6BF577D-768C-411A-84F5-83E3D480EAC1Q44565936-477D6B19-103C-4641-B9BD-7BA2343827AFQ46380663-E458552F-3ADC-4804-91BA-6416ED1574A9Q46521228-E256DE5D-8D1E-4ECB-877C-6C69757D95A5Q46907074-BC016957-AACE-4967-836D-96803A099294Q49792065-B5713ED8-7FD1-45BD-A574-3C895CA4BBDAQ51362513-F68D6AFC-8029-4727-BE7D-ED2D3C85CC79
P2860
Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@ast
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@en
type
label
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@ast
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@en
prefLabel
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@ast
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@en
P2093
P1476
Ether--lipid (alkyl-phospholip ...... lipid analogues in Leishmania.
@en
P2093
P356
10.1016/S0166-6851(00)00278-4
P577
2000-11-01T00:00:00Z